FDA's Bold Plan Could Revolutionize Rare Disease Therapies by 2025

The US Food and Drug Administration (FDA) has proposed new guidelines to speed up approvals for rare disease treatments. The draft pathway, called plausible mechanism, would allow experimental therapies—including gene editing—to reach patients faster. Officials aim to remove long-standing barriers that slow progress for conditions with few treatment options.

The proposed system targets therapies tested in very small patient groups. Unlike the current compassionate use programme, which bans commercial sales, this pathway would permit companies to sell approved treatments. The FDA's draft requires a clear understanding of the disease and a scientifically plausible reason to believe the therapy addresses its root cause.

FDA Commissioner Marty Makary emphasised the need for more cures and effective treatments. He noted that many rare diseases lack viable options because they don't fit traditional drug development models. The agency will accept public feedback on the draft for 60 days before finalising the rules.

As of March 2023, over 200 patients globally had received experimental CRISPR-based therapies. However, no updated figures exist for treatments that might qualify under the new FDA framework. The pathway could particularly benefit bespoke gene-editing approaches, where patient numbers are often too low for standard clinical trials.

The guidelines aim to bridge gaps in the current approval system. If adopted, they would enable faster commercialisation of therapies for rare conditions. The FDA expects the changes to encourage innovation while maintaining patient safety standards.